TCGA-BH-A0C3-01A-21R-A12P-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 90
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.420
- INTERFERON_ALPHA_RESPONSE+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
- UV_RESPONSE_DN+0.360
- INTERFERON_GAMMA_RESPONSE+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- KRAS_SIGNALING_UP+0.320
- ANGIOGENESIS+0.310
- FATTY_ACID_METABOLISM+0.310
Top 10 suppressed
- MYC_TARGETS_V1-0.440
- MYC_TARGETS_V2-0.420
- DNA_REPAIR-0.350
- E2F_TARGETS-0.270
- OXIDATIVE_PHOSPHORYLATION-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.200
- G2M_CHECKPOINT-0.160
- GLYCOLYSIS-0.130
- KRAS_SIGNALING_DN-0.110
- APICAL_SURFACE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-78-7160-01A-11R-2039-07 | — | cohortA4 | 0.861 |
| 2 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.843 |
| 3 | 6059e3d0-6430-4875-99df-9252a508974c | — | — | 0.835 |
| 4 | TCGA-44-6777-01A-11R-1858-07 | — | cohortA1 | 0.834 |
| 5 | BS_V89HGTET | pilocytic astrocytoma | — | 0.833 |
| 6 | BS_NRPG5K4K | low-grade glioma | — | 0.826 |
| 7 | 653522fe-3289-4e1f-9373-c81f923893a3 | — | — | 0.826 |
| 8 | SRR8518191 | — | D | 0.825 |
| 9 | SRR5088929 | — | — | 0.824 |
| 10 | TCGA-AC-A2B8-01A-11R-A17B-07 | — | A | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |